Introduction
Glioblastoma is a disease that remains difficult to treat, with inevitable recurrence after standard therapy, which includes surgery, radiotherapy, and temozolomide chemotherapy [1, 2] . For the lat-Despite these conceptual biological hurdles and complexities, there are arguments that speak for the use of anti-angiogenics in glioblastoma: The angiogenic and space-occupying core tumor mass often causes the most severe symptoms in patients, by regional disturbances of the brain function with neurological symptoms, increased intracranial pressure, and a particularly high growth rate. Furthermore, the peritumoral edema frequently aggravates the situation, and is responsible for space occupation and brain dysfunction by itself, which makes anti-VEGF-A therapy a plausible strategy (VEGF-A was originally dubbed 'vascular permeability factor', or VPF, highlighting its important role in tumor edema formation). And last but not least, other biological/targeted therapies have not proven effective in glioblastoma, so far. The empirical impression of a treatment benefit by bevacizumab, and also the well-documented increase of overall survival (OS) times of glioblastoma patients since bevacizumab was widely introduced into patient care in 2009, both in clinical and population-based studies [16] , made many neuro-oncologists believe that their great hopes were justified. The results of all controlled clinical trials, however, speak a somewhat different language. These discrepancies are the subject of ongoing controversies in the field and will be discussed in the following sections.
Bevacizumab in Glioblastoma
While antibody-based therapies targeting the tumor cells will always face the challenge of a non-permissive blood-brain/tumor barrier in the central nervous system (CNS), this appeared not to apply to the monoclonal anti-VEGF-A antibody, bevacizumab: Here, only the (abluminal) endothelial cells need to be reached to inhibit the binding of VEGF-A to its endothelial receptors. Full blood-brain barrier penetration is not necessary. In apparent support of these conceptual considerations, first clinical data of bevacizumab in malignant gliomas looked very promising, when compared to historical controls, particularly with respect to response rates [17] [18] [19] . This led to 2 phase III studies of bevacizumab given in parallel to standard radiochemotherapy in newly diagnosed glioblastoma; both confirmed a positive impact on progression-free survival (PFS) of 3-4 months, which did not reach the pre-specified significance level in the Radiation Therapy Oncology Group (RTOG) 0825 trial [20] , but did so in the Avastin in Glioblastoma (AVAglio) trial [21] . Furthermore, both trials showed a positive effect on survival time with no or low steroid co-treatment. While it is not disputed that bevacizumab can lower steroid use (and the associated negative impact on patient well-being) in clinical practice, the PFS results are frequently challenged because of the positive radiological effects of bevacizumab that might lead to a radiological 'pseudo-response' without having true impact on the tumor mass [22] . Even for those clinicians considering the PFS benefit of 3-4 months relevant, there was no doubt in both studies that OS was not affected by bevacizumab at all [20, 21] . Remarkably, both studies reported opposite effects on quality of life and patient performance: While the AVAglio trial found that health-related quality of life and performance status were maintained longer in the bevacizumab group, supporting the empirical impression of most neuro-oncologists, the RTOG 0825 trial found the opposite, with increased symptom burden, worse quality of life, and a decline in neurocognitive function being more frequent in the bevacizumab group over time. These conflicting results are a matter of ongoing debates.
The basic results of the AVAglio and the RTOG 0825 trials, with a PFS benefit of 3-4 months by bevacizumab without any detectable OS benefit (no median benefit and no long-term benefit), have been reproduced in all following glioblastoma trials with remarkable consistency. The randomized phase II GLARIUS trial [23] tested bevacizumab plus irinotecan versus standard temozolomide chemotherapy in prognostically unfavorable MGMT promotorunmethylated glioblastoma, where temozolomide has shown only very limited efficacy [3] . Here, PFS was improved by 3.7 months, without significant differences in OS or quality of life [24] . Finally, the randomized phase II ARTE trial investigated bevacizumab in elderly patients, together with radiotherapy versus radiotherapy alone. Conceptually, this was an interesting design because some had argued that bevacizumab might very well make radiotherapy more efficient but might indeed hinder temozolomide chemotherapy by re-erection of the blood-brain barrier, which would result in no net benefit if given in parallel to standard combined radiochemotherapy. However, the first results reported last year revealed a familiar picture contradicting this hypothesis: a PFS benefit of about 3 months and delayed clinical deterioration and reduced steroid use, without any detectable effect on OS when bevacizumab was added to radiotherapy [25] .
The reasons for the failure to translate PFS into an OS benefit are unclear. Potential explanations are that (i) the PFS benefit was mainly an imaging effect and no real gain in PFS, (ii) escape mechanisms of VEGF-inhibitory therapy made the recurrent tumor more aggressive, and/or (iii) there was a major impact of crossover, which for most practicing clinicians seemed the most logical explanation because the apparent benefit of glioblastoma patients re- ceiving bevacizumab, particularly as salvage therapy, appeared obvious. The results of the BELOB trial in recurrent glioblastoma, where crossover was not a relevant issue and promising OS results were detected for combined bevacizumab and lomustine (if not bevacizumab alone), seemed to support that notion [26] . Other support for this assumption comes from a secondary analysis of the AVAglio trial, where the PFS benefit from bevacizumab translated into an OS benefit of similar magnitude in the subgroup of patients that did not receive any further treatment after progression [27] .
While standard radiochemotherapy has relevant efficacy in newly diagnosed glioblastoma, no such therapy with proven efficacy in a phase III clinical trial exists for recurrent glioblastoma. Together with the decreased likelihood of crossover in this condition, most practicing clinicians expected an OS signal from the phase III European Organization for Research and Treatment of Cancer (EORTC) 26101 trial where bevacizumab plus lomustine was compared to lomustine alone, the latter being a standard therapy for glioblastoma recurrence in most European countries. But, again, the study results proved otherwise: a PFS benefit of 2.7 months, without significant differences in OS, quality of life, or neurocognitive function [28] .
On the basis of these results, the Food and Drug Administration (FDA) has recently granted bevacizumab full approval for recurrent glioblastoma in the USA, making the conditional approval of 2009 permanent. The European Medicines Agency (EMA), however, has repeatedly declined to approve bevacizumab for glioblastoma, and is not expected to change that decision. In clinical practice in many European countries, however, bevacizumab is still used, particularly in later stages of the disease, because many physicians continue to believe that there is a palliative benefit, a meaningful clinical benefit with improved neurological functioning and reduced steroid use, at least in selected patients. Those patients appear to be those with large tumor edema, a solid enhancing and well-circumscribed tumor, and edema-associated neurological disturbances. In any case, the strong empirical impression that certain patients seem very well to benefit from bevacizumab has fostered a plethora of research to better identify this patient subgroup.
Can We Better Select Patients with Biomarkers?
The striking similarities of the OS curves of the bevacizumab and control groups in all controlled glioblastoma studies performed so far speak for no net OS benefit whatsoever of the drug for the unselected patient population. Thus, conceptually, if the clinical impression is true and patient subgroup(s) exist that indeed enjoy an OS benefit from bevacizumab, others might very well be harmed by the same drug. This would make it even more important to identify and establish predictive biomarkers. However, no such clinically established, generally accepted biomarker does exist today. Like in other tumor entities, the simple expression of angiogenic target molecules, and also patterns of tumor vascularization, did not predict response to bevacizumab [29] . This lack of a predictive biomarker is clearly in sharp contrast to most other molecular therapies in oncology and might indeed be one explanation for the failure of anti-angiogenic therapies to prolong OS in unselected patients with malignant glioma.
The most straightforward biomarker would probably be a molecular one determined in the tumor tissue, even though this might be a rather complex business. An increasing body of data speaks for gene expression patterns that might correlate with response to bevacizumab. Analyzing glioblastoma patients from bevacizumab studies who were allocated to the Phillips gene expression subclasses [30] , it was first suggested that only the proneural subclass of isocitrate dehydrogenase (IDH)-wildtype glioblastomas might experience a relevant PFS and OS benefit from bevacizumab while the others did not [31] ; this was supported by recent data from elderly patients [25] . The IDH-wildtype proneural subclass shows the worst prognosis of all, which could speak for a particular relevance of bevacizumab for those patients who do not profit relevantly from the standard treatment today. Other published molecular biomarkers include a further analysis of the BELOB trial, where a particular gene expression signature that correlated more with the 'classical' glioblastoma subtype appeared to experience most clinical benefit from bevacizumab [32] . These discrepancies show that more work is needed for an unambiguous picture here, and, most importantly, a prospective validation of those biomarkers. This also applies to circulating factors like collagen IV, laminin, and progenitor cells, which have been suggested as predictive factors for anti-angiogenic therapies in glioma but have not yet been validated in larger studies [33] .
Another attractive biomarker could be imaging. It is non-invasive and can be repeatedly performed, which not only allows investigating how imaging parameters before start of anti-angiogenic treatment correlate with later response to that treatment but also how parameters dynamically change after the anti-angiogenic drug is initiated. Particularly the latter bears the promise of optimal insights into the dynamics of tumor response to anti-angiogenics and into the various subgroups (if existent) of patient response and outcome. In this context, it has been reported that early changes of magnetic resonance imaging (MRI) parameters can occur in glioblastoma patients who receive the anti-angiogenic multi-tyrosine kinase inhibitor cediranib, and those are in line with the normalization hypothesis (explained in the 'Introduction'), improving tumor perfusion, at least during a normalization time window, which might help radio-and chemotherapy [7, 10, [34] [35] [36] . For bevacizumab, however, it has been suggested that tumor oxygenation might actually be worsened and not improved in patients during the phase where vascular normalization occurs, which would speak against the benefit from vascular normalization for additional cytotoxic therapy in this condition [11] . Of note, multimodal MRI patterns analyzed by novel machine learning algorithms, i.e. large-scale radioomic profiling, might indeed provide a much clearer picture regarding benefit from anti-angiogenic drugs, as demonstrated for glioblastoma patients receiving bevacizumab [37] [38] [39] . Finally, from the analysis of the AVAglio data, it has been suggested that complete remission of contrast enhancement under treatment is associated with a better outcome [40] . All in all, while imaging biomark-ers certainly appear very interesting and in principle feasible in the clinical management of glioblastoma patients, there is a strong need to harmonize MRI protocols and analysis in order to be able to generalize findings from one study to patient stratification at multiple sites. Even when this is achieved, one would need to validate this imaging biomarker, complex or not, in a prospective clinical trial before patient stratification can be significantly influenced in the clinic or before it can be used for future therapeutic trials.
Other Clinical Trials with Anti-Angiogenic Agents in Glioblastoma
Besides bevacizumab, no other anti-angiogenic drug has found its way into clinical practice [41] . Mostly theoretical considerations related to the vascular normalization hypothesis led to a rush of the integrin inhibitor cilengitide to a phase III clinical trial in MGMTmethylated glioblastoma patients, who should profit most from cytotoxic therapy, despite a largely negative phase II trial. The phase III cilengitide trial, however, was also negative, with a complete lack of OS or PFS benefit compared to standard therapy in newly diagnosed glioblastoma [42] . Likewise, the protein kinase Cβ inhibitor enzastaurin, which has anti-angiogenic properties, failed in a phase III trial of recurrent [43] and also first-line [44] glioblastoma. VEGF receptor (VEGFR) inhibition by the tyrosine kinase inhibitor cediranib did also fail to meet the expectations and to prolong PFS and OS compared to standard lomustine chemotherapy in recurrent glioblastoma, although some clinical benefits like reduction of steroid use could be detected in this phase III study, not unlike what has been seen with bevacizumab [45] . Sunitinib also showed no relevant clinical activity in a single-arm phase II trial in recurrent glioblastoma [46] .
Potential Mechanisms of Resistance
Different mechanisms of resistance to anti-angiogenic therapy have been proposed in glioblastoma. Conceptually, primary resistance might occur when the angiogenic factor inhibited, be it VEGF-A or another, is not relevant for the disease, or at least not in this specific patient. Moreover, the fact that incurable gliomas like glioblastoma can progress very well without angiogenesis, effectively invading and colonizing the brain in a diffuse growth pattern [14, 15] , is most likely another mechanism by which primary resistance can occur. The diffusely infiltrative pattern of progression, however, might be associated with a slower cause of the disease, as it has been suggested by radiological patterns of recurrence of glioblastomas treated with bevacizumab [47] .
Multiple mechanisms of adaptive resistance to anti-angiogenic therapy have been suggested. Next to increased tumor invasion, activation of the c-Met tyrosine kinase pathway, shifts in cellular metabolism, induction of autophagy, augmentation of glioblastoma stem cell self-renewal, glioblastoma cell -endothelial cell transdifferentiation, and alternative vasoformative responses including vasculogenesis, alternative angiogenic pathways, and vascular mimicry have been described in various models [48] . The relevance of those for the human disease is, however, not clear. Figure 2 gives an example of a typical radiological pattern of response and development of resistance under bevacizumab, with a mixed angiogenic and diffuse recurrence at 6 months.
Summary and Outlook
Bevacizumab is the anti-angiogenic agent that continues to play a role in the treatment of glioblastoma. Many practicing clinicians regard its positive effect on PFS, other palliative effects like potential sparing of steroid dose, and the neurological improvement seen in many patients as meaningful benefits, even in the absence of any OS gain in the entire patient population. Hopes continue to rest on the identification of one or more patient subgroup(s) that benefit most, including with respect to OS. The optimal dose of bevacizumab is still not determined in glioblastoma, and might very well be lower than the 10 mg/kg every 2 weeks that is clinical practice [49, 50] . Pragmatically, bevacizumab with its documented beneficial effect on radionecrosis-related edema and neurological dysfunction [51] might be particularly interesting for the relevant number of patients where radiological and clinical deterioration might be rather caused by this not infrequent complication of standard therapy, frequently called 'pseudoprogression'. Several novel therapies under development, such as (combined) targeting of the angiopoietin pathway, and/or combinations with immunotherapies [41] are interesting, and their exploration for glioblastoma therapy continues. Fig. 2 . Radiological patterns of response and resistance in glioblastoma. 3 months after start of bevacizumab therapy, the contrast enhancement (T1 + CE) has largely resolved, and also the T2-FLAIR lesion is greatly decreased, mostly due to the anti-edema effects of the anti-VEGF-A agent. At month 6, new contrast enhancement (arrow, T1 + CE) and also solid non-enhancing tumor growth visible in the FLAIR sequence (arrow) occur. This speaks for a mixed recurrence pattern of both angiogenic and non-angiogenic (diffuse) relapse. 
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